Creative Medical Technology Holdings(CELZ)

PHOENIX, AZBiotechnology1 H-1B visas (FY2023)

Focus: Creative Medical Technology Holdings is a publicly traded stem cell therapy company focused on cell-based treatments for chronic pain and metabolic diseases. The company is in early-stage development with minimal revenue generation.

Cell Therapy

Profile data last refreshed 2h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Creative Medical Technology Holdings

AI assessmentNot Hiring

No open roles listed right now. Follow Creative Medical Technology Holdings to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$11K

FY2025

Pipeline & Clinical Trials

CELZ-201-DDT

Chronic Back Pain

N/A

Clinical Trials (1)

NCT07137559CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

N/A

Help build intelligence for Creative Medical Technology Holdings

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in stem cell therapeutics with public company resources and credibility
Focus on high-unmet-need indications (chronic back pain, Type 1 diabetes) with significant commercial potential
Early-stage pipeline allows for hands-on involvement in program development and clinical strategy

Watch Out For

Extreme R&D intensity (21,825%) relative to revenue ($11K FY2025) signals unsustainable burn rate and cash runway risk
Zero active job openings and minimal headcount data suggest the company is not actively hiring or may be in financial distress
Pre-clinical and Phase 1/2 pipeline with no Phase 3 programs means 5+ years minimum to potential commercialization

Generated by Claude from Creative Medical Technology Holdings's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Prior Burn Pit Exposure

Burn Pit Exposure

N/A

Clinical Trials (1)

NCT07562243Project PHOENIX: Molecular Signatures of Burn Pit Exposure

N/A

CELZ-201 Administration

Type 1 Diabetes

Phase 1/2

Clinical Trials (1)

NCT05626712Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

Phase 1/2

CELZ-201-DDT

Chronic Low-back Pain

Phase 1/2

Clinical Trials (1)

NCT06053242Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 4 clinical trials

Top TAs: Metabolic Diseases

H-1B (2023): 1 approval

SEC Filings: 2 available

Therapeutic Area Focus

Metabolic Diseases

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$11K22%

R&D Spend

$2M(21825%)22%

Net Income

-$5M

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo